The global histoplasmosis treatment market is estimated to grow at a CAGR of ~9% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing incidences of histoplasmosis, especially amongst few specific occupational groups. Histoplasmosis is a lung infection caused by a special kind of fungus found in the beat of bats and fowls. It is very common in construction workers, poultry farmers, and people with weakened immune systems. Histoplasmosis is also common among people suffering from HIV/AIDS. The growing prevalence of immune-deficiency diseases globally, is estimated to boost the market growth. According to the statistics by the World Health Organization (WHO), an estimated 37.7 million people were HIV positive, as of 2020, and over 1.5 million people acquired AIDS in 2020 itself.
The market is segmented by route of administration into oral, intravenous, and others, out of which, the intravenous segment is anticipated to hold the notable share in the global histoplasmosis treatment market over the forecast period on account of faster relief action of IV administration in chronic histoplasmosis. Based on type, the acute segment is anticipated to garner the largest share during the forecast period, owing to the high prevalence and easy transmission of the disease. Acute histoplasmosis is more common, which is estimated to boost the segment growth. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global histoplasmosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is estimated to witness noteworthy growth over the forecast period on the back of growing cases of chronic histoplasmosis backed by highest prevalence of AIDS in the region. According to a report by the WHO, 25.4 million people have AIDS in the WHO African Region, as of 2020.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the high prevalence of histoplasmosis across various regions of United States and Canada. According to the data by the Center of Disease Control and Prevalence (CDC), 60% to 90% of the population living in Ohio and Mississippi area were diagnosed of histoplasmosis at least once in their lifetime.
The global histoplasmosis treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global histoplasmosis treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The increasing cases of histoplasmosis is estimated to boost the market growth.
The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2022 – 2030.
Increasing circulation of generic drugs is estimated to hamper the market growth.
The market in the North America region is estimated to provide more business opportunities over the forecast period, owing to the higher prevalence of the disease in the region.
The major players in the market are Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, diagnosis, drug type, route of administration, and by region.
The acute segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization